Fortitude Family Office’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fortitude Family Office’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$27.6K	Buy	460 +357	+347%	+$22.5K	﹤0.01%	695
2026 Q2	$5.89K	Buy	103 +12	+13%	+$657	﹤0.01%	1001
2026 Q1	$5.14K	Buy	91 +56	+160%	+$3.27K	﹤0.01%	903
2025 Q4	$2.08K	Sell	35 -8	-19%	-$436	﹤0.01%	1161
2025 Q3	$2.33K	Buy	43 +5	+13%	+$286	﹤0.01%	1150
2025 Q2	$2.09K	Buy	38 +17	+81%	+$1K	﹤0.01%	1178
2025 Q1	$1.48K	Hold	21	–	–	﹤0.01%	969
2024 Q4	$1.38K	Buy	+21	New	+$1.41K	﹤0.01%	1086
2024 Q2	–	Sell	-9	Closed	-$786	–	976
2024 Q1	$786	Sell	9 -32	-78%	-$2.87K	﹤0.01%	912
2023 Q4	$3.95K	Buy	+41	New	+$3.63K	﹤0.01%	768

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

FFBTD

First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return

PCMU

Paragon Capital Management (Utah) Provo, Utah $132M AUM 24.83% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return

Fortitude Family Office's BMRN Position: Q3 2026 in Review

Fortitude Family Office increased its BioMarin Pharmaceuticals (BMRN) stake by 347% in Q3 2026, buying an estimated $22.5K and bringing the position to 460 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #695.

Fortitude Family Office first reported a position in BMRN in Q4 2023 and has held it in 10 quarters since. 42 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Fortitude Family Office held 460 shares of BioMarin Pharmaceuticals worth $27.6K as of Q3 2026.
Fortitude Family Office bought 357 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $22.5K.
BioMarin Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #695 holding.
Fortitude Family Office first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
42 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.